NCT06615752 Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
| NCT ID | NCT06615752 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Charles Drew University of Medicine and Science |
| Condition | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 99 participants |
| Start Date | 2026-10 |
| Primary Completion | 2028-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 99 participants in total. It began in 2026-10 with a primary completion date of 2028-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.
Eligibility Criteria
Inclusion Criteria: * Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization. * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male patients 18 years or older * Diagnosed with metastatic prostate cancer * History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration * Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate * Clinical decision to start doc infusion with prednisone treatment * Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³) * Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN) * Adequate renal function (serum creatinine level within normal limits) * At least a 6-month or greater life expectancy * Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention Exclusion Criteria: * Prior treatment of chemotherapy and/or radiotherapy for metastatic disease * Any comorbid condition that would preclude the administration of docetaxel/prednisone * Ongoing alcohol abuse * Significant medical or psychiatric conditions that would make the patient a poor protocol candidate * Prior allergic reaction to tea, tea products or quercetin supplements * Allergies to multiple food items or nutritional supplements
Contact & Investigator
Piwen Wang, PhD
PRINCIPAL INVESTIGATOR
Charles Drew University of Medicine and Science
Frequently Asked Questions
Who can join the NCT06615752 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Castration-resistant Prostate Cancer (mCRPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06615752 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06615752 currently recruiting?
Yes, NCT06615752 is actively recruiting participants. Contact the research team at PiwenWang@cdrewu.edu for enrollment information.
Where is the NCT06615752 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06615752 clinical trial?
NCT06615752 is sponsored by Charles Drew University of Medicine and Science. The principal investigator is Piwen Wang, PhD at Charles Drew University of Medicine and Science. The trial plans to enroll 99 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.